Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
暂无分享,去创建一个
J. Duyster | C. V. van Noesel | R. J. Reinten | T. V. van Os | R. Kancha | W. H. van der Ven | J. Weegenaar | P. Kunst | Jan van Noesel | Roy J. Reinten
[1] C. Peschel,et al. The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] Primitiva Menéndez,et al. Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: A novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma , 2011, BMC Cancer.
[3] C. Peschel,et al. Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy , 2009, Clinical Cancer Research.
[4] H. Koong,et al. Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] I. Wistuba,et al. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] Yih-Leong Chang,et al. Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response , 2008, Clinical Cancer Research.
[7] W. Pao,et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Koei Ikeda,et al. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. , 2008, The Annals of thoracic surgery.
[9] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[10] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[11] Alona Muzikansky,et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. , 2007, The oncologist.
[12] M. Tsuboi,et al. Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.
[13] M. Meyerson,et al. A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening , 2006, Clinical Cancer Research.
[14] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[15] Gayatry Mohapatra,et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR , 2005, Nature Genetics.